Rural health experts dig into the Trump administration’s effort to transform rural health care.

Guests:

• Kevin Bennett, Director Center for Rural & Primary Healthcare; Professor, Family and Preventative Medicine, School of Medicine Columbia, University of South Carolina
• Paula Chatterjee, Director of Health Equity Research, Penn LDI; Assistant Professor, Medicine, Perelman School of Medicine
• Sarah Jane Tribble, Chief Rural Correspondent, KFF Health News
• Rachel Werner, Executive Director, Leonard Davis Institute of Health Economics; Professor of Medicine, Perelman School of Medicine, University of Pennsylvania

Learn more and read a full transcript on our website.

Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.

Support this type of journalism today, with a gift.

Hosted on Acast. See acast.com/privacy for more information.

America pays less, on average, than any other major country for our generic drugs. But selling essential drugs at such low prices comes with hidden costs — from quality problems to frequent shortages.

This is the second episode of Race to the Bottom, a three-part series by Tradeoffs on the problems plaguing the generic drugs we all rely on — and how we could fix them.

Guests:

Christine Baeder, MBA, President, Apotex USA

Laura Bray, MBA, Founder, Angels for Change

Craig Burton, Senior Vice President of Policy and Strategic Alliances, Association for Accessible Medicines

Iilun Murphy, MD, Director of the Office of Generic Drugs, FDA

Leslie Walker, Senior Reporter/Producer, Tradeoffs

Marta Wosińska, PhD, Senior Fellow, Brookings Institution

Learn more and read a full transcript on our website.

Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.

Support this type of journalism today, with a gift.

Hosted on Acast. See acast.com/privacy for more information.

Generic drugs are, in many ways, the unsung hero of America’s health care system, bringing powerful medical innovations within the reach of millions more people. These cheaper copies of brand-name drugs — from pills that stop heart attacks to antibiotics that cure life-threatening infections — save America hundreds of billions of dollars a year. But will affordable, high-quality generic drugs continue to be there when we need them?

Some players are abandoning this business while others slash costs by cutting dangerous corners. Shortages of older generic drugs have become the norm, sending doctors scrambling. At the same time, crucial new medicines are proving tougher to copy on the cheap, saddling patients with brand-name prices.

Over the course of “Race to the Bottom,” our new three-part podcast series, we’ll explore why this industry that’s so essential to our health is in trouble — and what could change that.

In part one, we examine the history of this industry. Forty years ago this month, President Ronald Reagan signed groundbreaking, bipartisan legislation that gave birth to a new drug market. Lawmakers made choices back then that help explain the wild success and also the troubles we see today with generic medicines.

Guests:

Christine Baeder, MBA, President, Apotex USA

Alfred Engelberg, JD, retired attorney and former counsel to the Generic Pharmaceutical Association

Leslie Walker, Senior Reporter/Producer, Tradeoffs

Learn more and read a full transcript on our website.

Al Engelberg’s recently published memoir, “Breaking the Medicine Monopolies”, digs into the history of generic drugs.

Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.

Support this type of journalism today, with a gift.

Hosted on Acast. See acast.com/privacy for more information.